GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (OTCPK:BFFTF) » Definitions » Shiller PE Ratio

Biofrontera AG (Biofrontera AG) Shiller PE Ratio : (As of Jun. 24, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biofrontera AG Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Biofrontera AG Shiller PE Ratio Historical Data

The historical data trend for Biofrontera AG's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG Shiller PE Ratio Chart

Biofrontera AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biofrontera AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biofrontera AG's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera AG's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biofrontera AG's Shiller PE Ratio falls into.



Biofrontera AG Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Biofrontera AG's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Biofrontera AG's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.913/125.0381*125.0381
=-0.913

Current CPI (Mar. 2024) = 125.0381.

Biofrontera AG Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -2.865 99.543 -3.599
201409 -2.509 99.823 -3.143
201412 -2.400 99.543 -3.015
201503 -1.931 99.717 -2.421
201506 -4.898 100.417 -6.099
201509 -1.516 100.417 -1.888
201512 -1.421 99.717 -1.782
201603 -0.415 100.017 -0.519
201606 -2.093 100.717 -2.598
201609 -5.228 101.017 -6.471
201612 -2.513 101.217 -3.104
201703 -1.882 101.417 -2.320
201706 -3.076 102.117 -3.766
201709 -3.231 102.717 -3.933
201712 -0.926 102.617 -1.128
201803 -1.929 102.917 -2.344
201806 -2.285 104.017 -2.747
201809 -2.372 104.718 -2.832
201812 1.780 104.217 2.136
201903 -1.326 104.217 -1.591
201906 5.746 105.718 6.796
201909 -5.677 106.018 -6.695
201912 -2.173 105.818 -2.568
202003 -3.108 105.718 -3.676
202006 0.452 106.618 0.530
202009 -2.824 105.818 -3.337
202012 0.000 105.518 0.000
202103 -2.152 107.518 -2.503
202106 -1.694 108.486 -1.952
202109 -2.389 109.435 -2.730
202112 21.111 110.384 23.914
202203 -11.062 113.968 -12.136
202206 -4.699 115.760 -5.076
202209 -1.871 118.818 -1.969
202212 -0.667 119.345 -0.699
202303 -11.242 122.402 -11.484
202306 0.118 123.140 0.120
202309 -1.121 124.195 -1.129
202312 2.061 123.773 2.082
202403 -0.913 125.038 -0.913

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biofrontera AG  (OTCPK:BFFTF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Biofrontera AG Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Biofrontera AG's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofrontera AG (Biofrontera AG) Business Description

Traded in Other Exchanges
Address
Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Biofrontera AG (Biofrontera AG) Headlines